Australia's largest biotech company plans to expand its US presence with a $US1.5 billion ($A2.3 billion) investment that will allow it to manufacture more therapies ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

I entirely empathize with the hesitation to having a nurse stick a needle in your arm and become adjacent to a human juice ...